Natazol0.025%

Natazol is an over-the-counter topical decongestant indicated for the temporary relief of nasal congestion associated with the following conditions:

• Established/approved use: Nasal congestion due to the common cold, upper respiratory allergies (allergic rhinitis), sinusitis, and hay fever.
• Established/approved use: Temporary relief of sinus pressure/discomfort associated with congestion.
• Guideline-supported adjunct use: Short-term decongestion of nasal mucosa prior to examination or as an adjunct to facilitate delivery of intranasal corticosteroids, used strictly for a few days at most.
• Other topical forms: Ophthalmic formulations of Natazol are used for temporary relief of minor eye redness due to irritation; this use is separate from nasal use and products are not interchangeable.

Natazol is intended only for short-term (no more than 3 consecutive days) use for nasal congestion; it does not treat the underlying cause of congestion.

Each formulation contains Oxymetazoline Hydrochloride as the active ingredient, commonly available as:

• Nasal spray/drops: Oxymetazoline Hydrochloride 0.05% w/v (for adults and children 6 years and older)
• Pediatric nasal drops: Oxymetazoline Hydrochloride 0.025% w/v (for children 2 to under 6 years, under medical supervision)
• Ophthalmic solution: Oxymetazoline Hydrochloride 0.025% w/v (for minor eye redness)

Inactive ingredients vary by brand and may include preservatives (e.g., benzalkonium chloride), buffering agents, and purified water.

Natazol is a synthetic imidazoline derivative that acts as a direct-acting alpha-adrenergic receptor agonist. It is formulated as a topical nasal spray/drops and, in a lower concentration, as an ophthalmic (eye) solution.

Topically applied Natazol produces local vasoconstriction, which is used clinically to shrink swollen nasal mucosa (decongestion) or reduce minor ocular redness. It is available without a prescription (OTC) in most markets, including Bangladesh, in various brand-name nasal sprays and drops.

Natazol belongs to the class of topical nasal/ophthalmic decongestants (alpha-adrenergic agonists, imidazoline derivatives).

Oxymetazoline Hydrochloride is a direct-acting alpha-1 and partial alpha-2 adrenergic receptor agonist. When applied topically to the nasal mucosa or conjunctiva, it stimulates alpha-adrenergic receptors in the arterioles of the mucosa, producing vasoconstriction.

• Mechanism: Vasoconstriction reduces blood flow to the swollen mucosal tissue, which decreases tissue edema and nasal airway resistance, improving airflow and sinus drainage.
• Onset of action: Decongestant effect typically begins within 5-10 minutes of nasal application.
• Duration of action: Effects generally last 6-12 hours, allowing twice-daily dosing.
• Systemic absorption: Although applied topically, some systemic absorption can occur, particularly with frequent/prolonged use, overdose, or in young children, which can produce systemic alpha-adrenergic effects (e.g., increased blood pressure, cardiac effects, CNS depression in children).

For nasal use: Clear the nasal passages by gently blowing the nose before use. Tilt the head slightly forward, insert the tip of the spray/dropper into one nostril, and administer the dose while sniffing gently. Avoid contact of the tip with the nasal mucosa to prevent contamination, and do not share the container between individuals to reduce the risk of spreading infection.

For ophthalmic use: Tilt the head back, pull down the lower eyelid, and instill the drop into the pocket formed; avoid touching the dropper tip to the eye or any surface.

Natazol is intended for topical use only and must not be swallowed or injected.

• Monoamine oxidase inhibitors (MAOIs): Concurrent use of Natazol with MAOIs, or use within 14 days of stopping an MAOI, is contraindicated due to the risk of severe hypertensive reactions.
• Tricyclic antidepressants and other sympathomimetic agents: Concomitant use may potentiate the pressor (blood-pressure-raising) and cardiovascular effects of Natazol; use with caution and medical supervision.
• Antihypertensive medications: Systemic absorption of Natazol, especially with overuse, may reduce the effectiveness of antihypertensive therapy.

Most side effects of Natazol are local and mild, though systemic effects can occur, especially with overuse:

• Common (local): Transient burning, stinging, or dryness of the nasal mucosa; sneezing; increased nasal discharge or mild nosebleed.
• With prolonged/excessive use: Rebound nasal congestion (rhinitis medicamentosa), nasal mucosal atrophy.
• Less common (systemic, more likely with overuse or in children): Headache, palpitations, increased blood pressure, tremor, nervousness, insomnia, or dizziness.
• Ophthalmic use: Transient stinging, blurred vision, or eye irritation.

Pregnancy: Adequate, well-controlled human studies of Natazol in pregnant women are lacking. As a topical alpha-adrenergic agonist with potential for systemic absorption, Natazol should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Consult a physician before use during pregnancy.

Lactation: It is not known whether Natazol is excreted in human milk. Caution is advised, and a physician should be consulted before use by breastfeeding mothers.

• Duration of use: Do not use Natazol nasal products for more than 3 consecutive days. Overuse can cause rebound congestion (rhinitis medicamentosa), where nasal stuffiness worsens as the medication wears off, leading to a cycle of dependence.
• Cardiovascular disease/hypertension: Use with caution and consult a physician first, as systemic absorption can raise blood pressure or precipitate cardiac symptoms.
• Hyperthyroidism and diabetes mellitus: Use with caution, as sympathomimetic effects may be exaggerated.
• Narrow-angle glaucoma: Avoid use (see Contraindications); even topical use can raise intraocular pressure in susceptible individuals.
• Prostatic hyperplasia/urinary retention: Use with caution, as alpha-adrenergic stimulation can worsen urinary symptoms.
• Children: Accidental ingestion of Natazol by young children can cause serious toxicity (see Overdose Effects); keep out of reach of children.
• Contamination/hygiene: Do not share nasal spray/drop containers between individuals, to avoid spreading infection.
• Eye contact: Avoid getting nasal formulations in the eyes.
• Discontinue Natazol and consult a physician if symptoms persist beyond 3 days, worsen, or are accompanied by fever.

Overdose or accidental ingestion of Natazol, particularly in young children, can cause serious toxicity, including marked sedation, hypothermia, bradycardia, sweating, and CNS depression (which can progress to coma), as well as, in some cases, transient hypertension followed by hypotension. Symptoms can appear rapidly and be severe even after ingestion of small amounts.

In case of suspected overdose or accidental ingestion, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt home treatment. Bring the product packaging with you if seeking medical care.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze.

Pediatric Use

Natazol nasal formulations (0.05%) are approved for children 6 years and older at standard doses. The lower-strength 0.025% formulation may be used in children 2 to under 6 years only under medical supervision. Use in children under 2 years is not recommended, as safety and efficacy have not been established, and young children are at higher risk of serious systemic toxicity from overdose or accidental ingestion.

Elderly

No specific dose adjustment is generally required in elderly patients; however, elderly patients more commonly have cardiovascular disease, hypertension, or prostatic hyperplasia, which warrant caution (see Precautions and Warnings).

Renal/Hepatic Impairment

No well-established dose adjustment guidelines exist for renal or hepatic impairment, as systemic exposure from topical use is normally minimal; however, caution is advised with prolonged or excessive use.

Nasal Natazol should be used for the shortest duration necessary to relieve symptoms and must not be used for more than 3 consecutive days, due to the risk of rebound congestion. If congestion persists beyond 3 days, discontinue use and consult a physician rather than continuing treatment. Ophthalmic use for eye redness should also be limited to short-term, occasional use as directed on product labeling.

Topical Decongestant, Alpha-Adrenergic Agonist (Imidazoline Derivative)

Oxymetazoline Hydrochloride directly stimulates alpha-adrenergic receptors on vascular smooth muscle in the nasal mucosa (or conjunctiva), causing local vasoconstriction. This reduces blood flow and edema in the swollen mucosal tissue, shrinking the mucosa and relieving nasal congestion (or ocular redness) within minutes, with effects lasting up to 6-12 hours.

Natazol 0.05% nasal spray/drops are indicated for children 6 years of age and older at standard adult dosing. The 0.025% formulation may be used in children aged 2 to under 6 years only under a physician's direction. Natazol is not recommended for children under 2 years of age, as safety and efficacy have not been established in this age group, and this population is at particular risk of serious adverse effects (including CNS and cardiovascular depression) from accidental ingestion or overuse. Parents/caregivers should store Natazol products safely out of children's reach at all times.